GSK to buy phase III-ready drug efimosfermin from Boston Pharmaceuticals for as much as $2B British pharmaceutical company GSK (GSK) to acquire Boston Pharmaceuticals’ lead asset, efimosfermin ...

GSK Buys Rights to Phase III-Ready Liver Disease Candidate GSK announced that it is buying rights to clinical-stage biotech Boston Pharmaceuticals' lead pipeline candidate, efimosfermin alfa ...

GSK has agreed to pay $1.2 billion upfront to acquire rights to efimosfermin from Cambridge, Massachusetts-based Boston Pharmaceuticals, pledging another $800 million in milestone payments if the ...

currently with Boston Pharmaceuticals and Pfizer, which also involve 4-1BB bispecific proteins. Pfizer is developing SGN-BB228, a CD228/4-1BB candidate it inherited as part of its takeover of ...

U.S. President Donald Trump's trade negotiators are pushing the EU to make unilateral tariff reductions on U.S. goods, saying ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...

Torrent Pharmaceuticals is entering a new chapter as Aman Mehta, next-gen scion of the Mehta family, prepares to take over as ...

The move comes one day after the Trump administration announced it is revoking Harvard’s Student and Exchange Visitor Program ...

FRANKFURT, Germany (AP) — Danish pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said ...